Please login to the form below

Not currently logged in

Large antibody order for AbD Serotec

Proteomika SL has placed a large order for multi research antibodies with MorphoSys AG's AbD Serotec business unit.

Proteomika SL has placed a large order for multi research antibodies with MorphoSys AG's AbD Serotec business unit.

The Spanish biotech company, which specialises in biomarker technology, will be taking advantage of MorphoSys AG's HuCAL Gold (a powerful antibody library) based novel research antibodies.

This order will rank Proteomika, which is actively involved in cancer research/discovery programmes, as one of MorphoSys AG's largest customers

Dr Simon Moroney, CEO of MorphoSys AG, said: "This order is one of the largest generated by AbD Serotec, and highlights the advantage of our HuCAL technology in bespoke proteomics applications.

"We welcome the decision of Proteomika to use HuCAL Gold research antibodies in its proteomics programs."

A subsidiary of Progenika Biopharma SA, Proteomika was set up to exploit advances in biomarker research for the development of diagnostic and prognostic products.

Since its creation in 2002, the firm has established research collaborations with pharma and biotech companies aiming to validate non-invasive diagnostic and pharmacoproteomics.

Dr Laureano Simon, CEO of Proteomika, said: "The fast turn around in antibody production offered by AbD Serotec, together with the high quality of the resulting antibodies, will help accelerate the process of biomarker identification and validation."

Neither company involved in the deal has released financial details of the agreement.

5th March 2008


Featured jobs

Subscribe to our email news alerts


Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...